Avalo Therapeutics Inc (AVTX) Actualités

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX...

Form PRE 14A - Other preliminary proxy statements

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent...

Avalo Reports 2023 Financial Results and Provides Business Updates

Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024Increased cash position with private placement...

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 8-K - Current report